subscribeSubscribe
price-trendAsk Us
Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile

Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile
PHARMABIZ
27 May 2023
Share Share
FDA approves capmatinib for metastatic non-small cell lung cancer

FDA approves capmatinib for metastatic non-small cell lung cancer
US FPOOD & DRUG
10 Aug 2022
Share Share
Novartis lung cancer drug Tabrecta gets approval

Novartis lung cancer drug Tabrecta gets approval
John Pinching PHARMATIMES
22 Jun 2022
Share Share
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®)

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®)
BUSINESSWIRE
22 Apr 2022
Share Share
Novartis` Tabrecta gets EMA panel backing to treat lung cancer subtype in EU

Novartis` Tabrecta gets EMA panel backing to treat lung cancer subtype in EU
SEEKINGALPHA
22 Apr 2022
Share Share
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta)

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta)
BUSINESSWIRE
02 Sep 2020
Share Share
Novartis announces NEJM publication of pivotal study of Tabrectaâ„¢

Novartis announces NEJM publication of pivotal study of Tabrectaâ„¢
PRESS RELEASE
02 Sep 2020
Share Share
FDA starts quick review of Merck’s MET-targeting lung cancer drug

FDA starts quick review of Merck’s MET-targeting lung cancer drug
Phil Taylor PHARMAPHORUM
28 Aug 2020
Share Share